Product Details
| Product Name:
Lipopolysaccharides |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Lipopolysaccharides |
| Description | Lipopolysaccharides (LPS) derived from Escherichia coli 055:B5, are a unique component of the cell wall of Gram-negative bacteria. They are composed of three regions: lipid A, oligosaccharide core, and O-specific polysaccharide (O-antigen). Lipopolysaccharides help maintain the integrity of the cell outer membrane and protect bacteria from damage by bile salts and lipid antibiotics. Lipopolysaccharides are highly immunogenic antigens that can enhance immune responses and can be used to construct inflammatory models. |
| In vitro | METHODS: Human lung mucoepidermoid carcinoma cells H292 and monocytes THP-1 were treated with Lipopolysaccharides (1-20 μg/mL) for 6-48 h. Cytotoxicity was detected by MTT.
RESULTS: No significant changes in the viability of H292 cells treated with 1 and 2.5 μg/mL Lipopolysaccharides and THP-1 cells treated with 1 and 2 μg/mL Lipopolysaccharides were observed. Lipopolysaccharides at higher concentrations (5-20 μg/mL) were significantly cytotoxic to both H292 and THP-1 cells. [1]
METHODS: Human induced pluripotent stem cell-derived cardiomyocytes hiPSC-CMs were treated with Lipopolysaccharides (0.1-100 μg/mL) for 6-48 h. Inflammatory cytokine expression was detected by qRT-PCR.
RESULTS: The mRNA expression level of IL-1β was increased at 6 h of Lipopolysaccharides treatment, IL-10 was increased only at 48 h, and TNF-α and IL-6 were increased at both 6 and 48 h. [2]
METHODS: Neutrophils were treated with Lipopolysaccharides (10 mg/ml) for 4 h. The expression levels of target proteins were measured by Western Blot.
RESULTS: The expression of H3-cit and TLR4 increased after treatment with Lipopolysaccharides, which induced the formation of neutrophil extracellular traps (NETs) in neutrophils. [3] |
| In vivo | METHODS: To construct a mouse model of sepsis, Lipopolysaccharides (25 mg/kg) were administered to C57/BL mice by a single intraperitoneal injection.
RESULTS: Lipopolysaccharides induced significant up-regulation of inflammatory factors TNF-α and IL-1β. Lipopolysaccharides induced sepsis in a mouse model. [4]
METHODS: To investigate the effects of Lipopolysaccharides on cognitive deficits and neuroinflammation, Lipopolysaccharides (500-750 μg/kg in saline) were injected intraperitoneally into C57BL/6J mice once daily for seven days.
RESULTS: Lipopolysaccharides treatment resulted in disease behavior and cognitive deficits in mice, and these effects were accompanied by microglia activation and neuronal cell loss in the hippocampus. Lipopolysaccharides treatment decreased serum and brain homogenate levels of IL-4 and IL-10, and increased levels of TNF-α, IL-1β, PGE2, and NO levels were increased. [5] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 5 mg/mL (Need ultrasonic)
|
| Keywords | Lipopolysaccharides |
| Related Compound Libraries | Microbial Natural Product Library | NO PAINS Compound Library | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:93572-42-0
$68.00 / 1mg
-
CAS:1065124-65-3
$39.00 / 1mg
-
CAS:1270084-92-8
$51.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$45.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States